Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Summary by Relevant Sections Lawsuit Allegations - The lawsuit claims that MoonLake misled investors by asserting that the unique Nanobody structure of sonelokimab would provide superior clinical outcomes compared to traditional monoclonal antibodies, specifically against the FDA-approved BIMZELX [3]. Stock Performance - Following the announcement of the VELA-2 trial results, which failed to meet its primary endpoint and demonstrated inferior efficacy, MoonLake's stock plummeted from $61.99 to $6.24, representing a 90% loss [4]. Investor Actions - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to explore legal options and the possibility of becoming the Lead Plaintiff [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, which announced that the U.S. FDA issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, indicating deficiencies that must be resolved before approval [3]. - Following the announcement of the CRL, Alvotech's stock price experienced a significant decline, falling 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified class period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6] - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who bought Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 9, 2026 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of misleading statements regarding its product SLK and its comparison to BIMZELX, which led to significant stock price decline following disappointing clinical trial results [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - The firm is investigating claims against MoonLake and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the efficacy of SLK compared to BIMZELX [4]. Group 2: Financial Impact - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to BIMZELX, resulting in a stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [5]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 3: Company Background - MoonLake Immunotherapeutics is listed on NASDAQ under the ticker MLTX [2]. - The company is involved in the development of therapeutics, specifically focusing on Nanobodies and their clinical applications [4].

RT Neuralink (@neuralink)ALS is a neurodegenerative disease that gradually and relentlessly takes away bodily functions, such as the ability to speak.With Neuralink, we aim to restore the voices of those who have lost them. ...

Core Insights - Alnylam Pharmaceuticals has faced challenges in the last three months due to slowing sales at a key rival, raising concerns about the overall health of the transthyretin amyloidosis (TTR) market [1] Company Summary - Alnylam Pharmaceuticals is experiencing difficulties linked to competitive pressures in the TTR space, which may impact its market position and sales performance [1]

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][3][4]. Summary by Sections Lawsuit Details - The lawsuit claims that MoonLake's assertions regarding the superiority of its Nanobody technology were misleading, particularly in comparison to the FDA-approved competitor BIMZELX [3]. - The stock price plummeted from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and demonstrated inferior efficacy [4]. Timeline and Key Information - Class Period: March 10, 2024 – September 29, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Significant Stock Drop: 90% loss on September 29, 2025, due to failed trial results [4]. Next Steps for Investors - Investors who purchased MoonLake stock during the specified class period and incurred substantial losses are encouraged to contact Hagens Berman to explore legal options and potential appointment as Lead Plaintiff [5]. About Hagens Berman - Hagens Berman is a global plaintiffs' rights firm that focuses on corporate accountability and has secured over $2.9 billion for clients in similar cases [7].

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit covers all individuals and entities who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [8] - The complaint highlights that MoonLake's executives touted SLK's unique clinical advantages without revealing that it targeted the same molecules as UCB's BIMZELX [8] - The stock plummeted 89.9% on September 29, 2025, after the company disclosed that the VELA-2 trial did not achieve statistical significance due to unexpected events in the placebo group [8] Next Steps - Investors who suffered losses and wish to participate in the lawsuit must apply to the Court by December 15, 2025, to be appointed as lead plaintiff [8] - Interested parties can contact Bragar Eagel & Squire, P.C. for more information regarding their rights and the claims [4][5]

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best performers on Friday. ImmunityBio jumped by 7.76 percent on Friday to close at $2.36 apiece after securing the green light of the European Medicines Agency (EMA) to sell its bladder cancer treatment Anktiva in Europe. In a statement, ImmunityBio Inc. (NASDAQ:IBRX) said that the EMA officially authorized Anktiva, in combination with Bacillus Calmette-Guerin (BCG), for th ...